PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

PetVivo will hold a conference call on June 28, 2024, at 5:00 p.m. ET to discuss fiscal Q4 and annual results ended March 31, 2024. The financial results will be released prior to the call. Management will present and answer questions. Dial-in and webcast replay options are available.

PetVivo Holdings has appointed Bryan Monninger as their new VP of Sales. Monninger brings over 20 years of experience in sales and marketing, including senior roles at NOVUS, Colgate-Palmolive, Lintbells, and ConAgra. He will lead PetVivo's sales and distribution teams to expand the market adoption of their animal osteoarthritis product, Spryng™ with OsteoCushion™ Technology. Monninger's extensive background includes successful market entries, strategic planning, and sales growth acceleration. CEO John Lai expects Monninger's expertise to drive PetVivo's growth and expand their market reach both domestically and internationally.

PetVivo Holdings announced that April Boyce has joined as Vice President of Marketing. Boyce, with over 20 years of experience in consumer-packaged goods (CPG) marketing, sales, and strategic partnerships, has held significant roles at Procter & Gamble and Clorox. At Clorox, she led the shopper marketing division and formed strategic partnerships with companies like Burt's Bees, Coca-Cola, and Tyson Foods. Her most recent role was Chief Commercial Officer at pet tech start-up, Link. Boyce aims to enhance awareness and understanding of PetVivo's veterinary medical device, Spryng with OsteoCushion Technology.

PetVivo Holdings, Inc. will be a Silver Sponsor at the IVAPM Pain Management Forum to exhibit its lead product, Spryng™ with OsteoCushion™ Technology. The clinical studies on Spryng show significant improvements in dogs with joint diseases, making it a promising veterinary medical device for osteoarthritis management.

PetVivo Holdings, Inc. will showcase its innovative veterinary medical device, Spryng, with OsteoCushion Technology at the ACVSMR Symposium. Spryng aims to manage joint pain in pets by promoting proper joint mechanics. CEO John Lai expresses excitement for the opportunity to present Spryng at the event.

PetVivo Holdings, Inc. announces its participation in the ACVSMR Symposium to showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, aimed at managing joint pain in pets. The event will be held from April 11th to April 13th, 2024, in Naples, Florida.

PetVivo Holdings, Inc. appoints Garry Lowenthal as the new Chief Financial Officer, bringing over 25 years of extensive experience in finance management and operations. Mr. Lowenthal's background includes leading equity capital raising transactions for private and public companies, serving on the national board of Financial Executives International, and working for top CPA/Consulting firms like PricewaterhouseCoopers and Deloitte.

PetVivo Holdings, Inc. dual lists on Upstream's global securities trading app, providing digital-first investors worldwide with streamlined access to PETV shares. The company's free NFT commemorating the listing is available for all Upstream participants. Non-U.S. investors can deposit or trade PETV securities on Upstream, with trading starting after the first offer is placed. The market operates 5 days a week, 20 hours a day, offering real-time trading and settlement with transparent orderbooks.

PetVivo Holdings, Inc. announced the successful completion of the first cohort of dogs in a clinical study focusing on the benefits of an intra-articular injection of collagen-elastin hydrogel microparticles for dogs with osteoarthritis. The study showed promising results with significant improvements in CBPI scores, hip extension, visual lameness scores, and quality of life assessments. Spryng™ with OsteoCushion™ Technology appears to be a viable option for managing coxofemoral joint osteoarthritis in companion animals.